Lee Ainslie Verona Pharma PLC Transaction History
Maverick Capital LTD
- $5.08 Billion
- Q1 2025
A detailed history of Lee Ainslie (Maverick Capital LTD) transactions in Verona Pharma PLC stock. As of the latest transaction made, Maverick Capital LTD holds 1,783,498 shares of VRNA stock, worth $134 Million. This represents 2.23% of its overall portfolio holdings.
Number of Shares
1,783,498
Previous 3,128,516
42.99%
Holding current value
$134 Million
Previous $145 Million
22.06%
% of portfolio
2.23%
Previous 2.81%
Shares
6 transactions
Others Institutions Holding VRNA
# of Institutions
291Shares Held
74.3MCall Options Held
933KPut Options Held
1.98M-
Perceptive Advisors LLC New York, NY6.56MShares$493 Million17.44% of portfolio
-
Janus Henderson Group PLC London, X05.52MShares$414 Million0.2% of portfolio
-
Darwin Global Management, Ltd. St. Helier, Y93.92MShares$294 Million17.31% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.46MShares$260 Million13.82% of portfolio
-
Eventide Asset Management, LLC Boston, MA2.89MShares$217 Million3.9% of portfolio
About Verona Pharma plc
- Ticker VRNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,954,200
- Market Cap $4.58B
- Description
- Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...